Drug intelligence / Profile preview

4-POpsilocin

Development stage: Preclinical
Lead developer: Nirvana Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

4-POpsilocin is a novel psychoactive substituted tryptamine and metabolic prodrug of psilocin (and potentially psilocybin) being developed by Nirvana Life Sciences. It is designed to provide a shorter psychedelic experience of approximately four hours with a reduced "body load" compared to naturally occurring psilocybin. The compound is currently in the preclinical stage, with development focused on applications within the clinical pharmaceutical market, particularly for addiction treatment. Nirvana Life Sciences is in the process of finalizing patents for the compound's exclusive use and intends to deploy it as part of a broader addiction-focused therapeutic pipeline.

Other names: 4-PO psilocin

Targets

5-HT2C (5-hydroxytryptamine receptor 2C)HTR1D (5-hydroxytryptamine receptor 1D)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on 4-POpsilocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-POpsilocin.

Explore the full profile